Validation for Revision of the Stage IIIA(T1N2) in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2025 Mar 13

PMID 40075384

Authors

Tong Wu

Jingsheng Cai

Yun Li

Rongjing Xie

Kezhong Chen

Affiliations

Soon will be listed here.

Abstract

Objectives: The 9th edition of the lung cancer tumor-node-metastasis (TNM) staging system downgrades certain non-small cell lung cancer (NSCLC) patients from stage IIIA (T1N2) to IIB(T1N2a). This study aimed to externally validate this stage adjustment.

Methods: Consecutive resected stage IIB and IIIA (the 9th edition of lung cancer TNM staging manual) NSCLC patients were included. Stage IIB was divided into groups A, B, and C according to lymph node involvement. Group A, patients who having single-station N2 without N1 involvement; Group B, patients who having single-station N2 with N1 involvements; Group C, patients who having station N1 involvement or N0. The stage IIIA patients divided into Group D. Overall survival (OS) and disease-free survival (DFS) were compared using the Kaplan-Meier method, with propensity score matching (PSM) employed to mitigate potential biases. COX regression models were utilized to assess prognostic differences.

Results: 224 stage IIB and 227 stage IIIA cases was included. There were 38, 66 and 120 patients in the Group A, B and C, respectively. Univariate COX analysis indicated comparable prognoses between the Group A and Group C patients, whereas Group B patients exhibited poorer outcomes. Upon combining the Group A and Group C patients, multivariate COX analysis demonstrated a significantly worse prognosis for Group B patients compared to those with Group A + C patients (OS, P = 0.035; DFS, P = 0.021). Further comparisons between Group B and Group D patients, following PSM analysis, indicated similar survivals (OS: P = 0.390; DFS: P = 0.210).

Conclusion: In the 9th edition of the lung cancer TNM staging system, the prognosis of stage IIB N2a2 patients was worse than that of remaining stage IIB patients but comparable to that of stage IIIA patients. We proposed that stage IIB N2a2 patients should be maintained as stage IIIA.

References

Schlachtenberger G, Schallenberg S, Doerr F, Menghesha H, Gaisendrees C, Amorin A . Do skip-N2 metastases significantly impact overall survival and disease-free interval in N2 non-small-cell lung cancer patients? A multicentre analysis. Eur J Cardiothorac Surg. 2023; 64(1). DOI: 10.1093/ejcts/ezad247. View

Cai J, Li Y, Wang X . Is prior cancer history a hindrance for non-small cell lung cancer patients to participate in clinical trials?. BMC Cancer. 2023; 23(1):155. PMC: 9930244. DOI: 10.1186/s12885-023-10551-9. View

Miyawaki T, Kenmotsu H, Doshita K, Kodama H, Nishioka N, Iida Y . Clinical impact of tumour burden on the efficacy of PD-1/PD-L1 inhibitors plus chemotherapy in non-small-cell lung cancer. Cancer Med. 2022; 12(2):1451-1460. PMC: 9883568. DOI: 10.1002/cam4.5035. View

Cai J, Yang F, Wang X . Reconsidering the T category for the T3 non-small cell lung cancer with additional tumor nodules in the same lobe: A population-based study. Front Oncol. 2023; 13:1043386. PMC: 10113646. DOI: 10.3389/fonc.2023.1043386. View

Imai K, Minamiya Y, Saito H, Nakagawa T, Ito M, Ono T . Detection of pleural lymph flow using indocyanine green fluorescence imaging in non-small cell lung cancer surgery: a preliminary study. Surg Today. 2012; 43(3):249-54. DOI: 10.1007/s00595-012-0237-2. View

Wang X, Guo H, Hu Q, Ying Y, Chen B . The Impact of Skip vs. Non-Skip N2 Lymph Node Metastasis on the Prognosis of Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. Front Surg. 2021; 8:749156. PMC: 8546110. DOI: 10.3389/fsurg.2021.749156. View

Cai J, Li Y, Yang F, Wang X . Investigation of the non-size-determined T4N0-2M0 non-small-cell lung cancer: what is the proper T category for the tumour with additional nodules in different lobes of ipsilateral lung?. Eur J Cardiothorac Surg. 2023; 64(1). DOI: 10.1093/ejcts/ezad243. View

Cai J, Yang F, Wang X . Occult lymph node metastasis is not a favorable factor for resected NSCLC patients. BMC Cancer. 2023; 23(1):822. PMC: 10476354. DOI: 10.1186/s12885-023-11189-3. View

Taylor M, Soliman N, Paoletti E, King M, Crosbie P, Granato F . Impact of skip mediastinal lymph node metastasis on outcomes after resection for primary lung cancer. Lung Cancer. 2023; 184:107341. DOI: 10.1016/j.lungcan.2023.107341. View

10.

Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt W . The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016; 11(1):39-51. DOI: 10.1016/j.jtho.2015.09.009. View

11.

Cai J, Lin Q, Dou X . Is adjacent lobe invasion an T category upgrade factor for resected non-small cell lung cancer ≤ 5 cm?. J Cancer Res Clin Oncol. 2022; 149(5):1777-1784. DOI: 10.1007/s00432-022-04102-1. View

12.

Fong K, Rosenthal A, Giroux D, Nishimura K, Erasmus J, Lievens Y . The International Association for the Study of Lung Cancer Staging Project for Lung Cancer: Proposals for the Revision of the M Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2024; 19(5):786-802. DOI: 10.1016/j.jtho.2024.01.019. View

13.

Cai J, Yang F, Wang X . Is there a prognostic difference among patients with T3N0-3M0 non-small-cell lung cancer with different T3 descriptors?. Eur J Cardiothorac Surg. 2022; 63(3). DOI: 10.1093/ejcts/ezac558. View

14.

Rami-Porta R, Nishimura K, Giroux D, Detterbeck F, Cardillo G, Edwards J . The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groups in the Forthcoming (Ninth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2024; 19(7):1007-1027. DOI: 10.1016/j.jtho.2024.02.011. View

15.

Bray F, Laversanne M, Sung H, Ferlay J, Siegel R, Soerjomataram I . Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3):229-263. DOI: 10.3322/caac.21834. View

16.

Li X, Li X, Fu X, Liu L, Liu Y, Zhao H . Survival benefit of skip metastases in surgically resected N2 non-small cell lung cancer: A multicenter observational study of a large cohort of the Chinese patients. Eur J Surg Oncol. 2020; 46(10 Pt A):1874-1881. DOI: 10.1016/j.ejso.2019.12.015. View

17.

Xu L, Su H, She Y, Dai C, Zhao M, Gao J . Which N Descriptor Is More Predictive of Prognosis in Resected Non-small Cell Lung Cancer: The Number of Involved Nodal Stations or the Location-Based Pathological N Stage?. Chest. 2020; 159(6):2458-2469. DOI: 10.1016/j.chest.2020.12.012. View

18.

Riquet M, Hidden G, DEBESSE B . Direct lymphatic drainage of lung segments to the mediastinal nodes. An anatomic study on 260 adults. J Thorac Cardiovasc Surg. 1989; 97(4):623-32. View

19.

Cai J, Wang X, Yang F, Li Y, Qiu M . Lymphovascular invasion: A non-sized T descriptor for stage IA non-small cell lung cancer. Thorac Cancer. 2022; 13(17):2413-2420. PMC: 9436680. DOI: 10.1111/1759-7714.14530. View

20.

Huang B, Wang W, Cai J, Zhang S . Investigations of the distant metastatic non-small cell lung cancer without local lymph node involvement: Real world data from a large database. Clin Respir J. 2023; 17(8):780-790. PMC: 10435941. DOI: 10.1111/crj.13668. View